Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.
about
Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancerThe emerging role of the LIV-1 subfamily of zinc transporters in breast cancerExpanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitizationAt the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of boneReview of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrantHormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal WomenSelective regain of egfr gene copies in CD44+/CD24-/low breast cancer cellular model MDA-MB-468.A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2.New steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death.The relationship between prognostic and predictive factors in the management of breast cancer.Inferring predominant pathways in cellular models of breast cancer using limited sample proteomic profiling.Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesEGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.Role of HER2 gene overexpression in breast carcinoma.VAV3 mediates resistance to breast cancer endocrine therapy.Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer.Apoptosis and autophagy in breast cancer cells following exemestane treatment.Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice.Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of actionerbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines.Phosphatidic Acid Increases Epidermal Growth Factor Receptor Expression by Stabilizing mRNA Decay and by Inhibiting Lysosomal and Proteasomal Degradation of the Internalized ReceptorThe Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer.Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancerExpression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas.Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenograftsHIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells.ADP-ribosylation factor 1 controls the activation of the phosphatidylinositol 3-kinase pathway to regulate epidermal growth factor-dependent growth and migration of breast cancer cellsSteroid hormone receptors and their clinical significance in cancer.Anti-epidermal growth factor receptor strategies for advanced breast cancer.Propolis and its Active Component, Caffeic Acid Phenethyl Ester (CAPE), Modulate Breast Cancer Therapeutic Targets via an Epigenetically Mediated Mechanism of ActionPerfluorinated chemicals, PFOS and PFOA, enhance the estrogenic effects of 17β-estradiol in T47D human breast cancer cells.Bcl-2 expression and triple negative profile in breast carcinoma.Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain.GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways.Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways.Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896.
P2860
Q24642830-0C7D866F-0CF1-4354-8EDB-F47C1D276B91Q24682854-40E78C47-AA80-43AB-AA23-988E635CE8DDQ24803435-81BAF283-929F-4697-A8FA-91D6D502F4E4Q26866067-915D0573-E969-4BC5-B81D-8EC2A742E34CQ28076777-D0FA672F-4BB4-4E5D-AA9D-959251014A2DQ28077637-210A3108-B77E-4CF1-A6CB-C3B9FE4593BEQ30978860-0AE0FFF6-EAA3-4FF7-B5F8-D155E45ECF3FQ33208837-1702ECA2-B1F8-4097-8935-059B22802862Q33354763-173FE8E2-7B43-4403-8FA7-17E413944F97Q33538455-22EDCCDB-06B7-4DBB-BF3D-55F61691D19EQ33605369-04A76706-EBB6-433C-94FF-9BCA39EB7045Q33691211-34BB7CE3-1D12-409F-BEC4-A9BFEFB2D811Q33793142-82849FE3-11CF-4129-A616-172646E84A2CQ33810080-5F982DD6-8A5F-48B7-92C2-6345DA4FB45EQ33827037-AA9E9A96-A2F7-4DD9-9860-94CC46976D77Q33842800-8FB04204-D4B1-47D4-A5F5-E6C7CB588C9EQ34388747-6A83E0CA-E034-43EC-B7C0-CE5CB4A134EDQ35029583-565AFB72-68CF-4279-B37C-04EA44EAFF1DQ35558954-782723FD-EEA0-4471-99A6-4FBBAB5A4622Q35559032-7354C871-52DB-4222-999F-7DCD6C1489D8Q35683561-9073AF21-6D8E-4F2F-8ED5-4395FB4F7D11Q35963792-950637E2-7960-491F-B034-ADBEF560A513Q35982925-2D7C5F2E-C26F-4943-A020-AEEECFD83554Q36081088-B68F2932-C42C-43A2-BC63-06F798643CCDQ36081269-0F41B011-D38B-4E4B-8D48-0DA4AEF638E0Q36393289-9C30F16D-2704-45FF-B191-B40FFBC8E3C9Q36653598-8DF2A361-3799-4E7E-AAFB-ECE1AFFF905AQ36787372-BC2175C6-D104-49A1-9135-EB25032444B9Q36916606-EBE48198-C746-4243-90CB-3A301BA9916CQ36998209-65FC6D8B-588C-4DE2-B8C7-A7526410297CQ37142842-8ADAC7AB-4630-4AE8-B542-B2A9B4DA1D4BQ37268503-73BCD713-999D-4394-8513-1B9C7D640C49Q37293327-9C2D1A63-7283-4F36-972C-6144F65C8833Q37503537-1E610BEC-44AE-4CF8-8AB6-2A0869580DB9Q38847297-9F115A64-8F3B-4274-A1D0-70C80FECA311Q39116598-30DF9E85-902A-460F-96A1-7F1D872BF6FAQ39709408-059BBE97-DB70-4C22-8C8B-D47D7805002DQ40373265-E5E90269-8F78-4A6B-952F-A6B658F7B41CQ40995230-DE8E737F-FF16-4F5B-9727-23015A10B66FQ40999403-B9779491-DC03-42E3-B350-8EFF0D046098
P2860
Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Epidermal growth factor recept ...... response to endocrine therapy.
@en
Epidermal growth factor recept ...... response to endocrine therapy.
@nl
type
label
Epidermal growth factor recept ...... response to endocrine therapy.
@en
Epidermal growth factor recept ...... response to endocrine therapy.
@nl
prefLabel
Epidermal growth factor recept ...... response to endocrine therapy.
@en
Epidermal growth factor recept ...... response to endocrine therapy.
@nl
P2093
P356
P1476
Epidermal growth factor recept ...... response to endocrine therapy
@en
P2093
D L Manning
J F Robertson
R A McClelland
R I Nicholson
R W Blamey
P2888
P304
P356
10.1007/BF00666187
P407
P577
1994-01-01T00:00:00Z